Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 5/20 | 0.49 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.31 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.30 |
| ▸ | RAF1 | P04049 | 1/20 | 0.30 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.30 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
| ▸ | SLC6A7 | Q99884 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14840577 | 0.84 | PRCP (0.63) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849784 | 0.76 | PRCP (0.59) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849812 | 0.76 | PRCP (0.59) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849787 | 0.76 | PRCP (0.59) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849808 | 0.76 | PRCP (0.59) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14840859 | 0.75 | PRCP (0.66) | PRCPMAPK11MAPK14SLC6A7 | |
| SCHEMBL14840905 | 0.69 | PRCP (0.63) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849781 | 0.67 | PRCP (1.00) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849783 | 0.67 | PRCP (1.00) | PRCPMAPK13RAF1MAPK12MAPK11 | |
| SCHEMBL14849776 | 0.66 | PRCP (0.57) | PRCPCHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011156246-A1 | NOVEL PROLYLCARBOXYPEPTIDASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-12-15 | — | — | WO | disclosed |